Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data - 20/08/20
Doi : 10.1016/j.therap.2020.05.001
Aurélie Grandvuillemin a, ⁎ 
, Audrey Fresse b, Clément Cholle a, Samir Yamani b, Anne Dautriche a
, Audrey Fresse b, Clément Cholle a, Samir Yamani b, Anne Dautriche aFrench Network of Regional Pharmacovigilance Centres
a Centre régional de pharmacovigilance de Bourgogne, pôle des vigilances, centre hospitalier universitaire, 21079 Dijon, France
b Centre régional de pharmacovigilance de Nice-Alpes Côte d’Azur, 06003 Nice, France
⁎Corresponding author. Centre regional de pharmacovigilance de Bourgogne, pôle des vigilances, centre hospitalier universitaire, 14, rue Paul-Gaffarel, 21079 Dijon cedex, France.Centre regional de pharmacovigilance de Bourgogne, pôle des vigilances, centre hospitalier universitaire14, rue Paul-GaffarelDijon cedex21079France
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Keywords : Hydroxychloroquine, Pharmacovigilance, Adverse reaction
Il testo completo di questo articolo è disponibile in PDF.
Mappa
© 2020
Société française de pharmacologie et de thérapeutique. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 75 - N° 4
P. 385-387 - luglio 2020 Ritorno al numero
Articolo precedente
- Chloroquine and hydroxychloroquine during pregnancy: What do we know?
- Isabelle Lacroix, Justine Bénévent, Christine Damase-Michel
- NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection
- Medine Cumhur Cure, Adem Kucuk, Erkan Cure
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.